HCPCS Level II code J9264 denotes the injectable chemotherapy agent paclitaxel protein-bound particles, billed per 1 mg unit. This code captures administration of albumin-bound paclitaxel (nab-paclitaxel), a formulation used in multiple oncology settings. Nationally, accurate coding for this agent matters for clinical documentation, appropriate reimbursement, and tracking utilization of a high-cost biologic chemotherapy.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the drug, typical sites of service where the product is administered, and the common payer landscape relevant to coverage and billing. The publication summarizes benchmarks and payment policy considerations, highlights typical billing workflows for an injectable chemotherapy agent, and outlines areas where payers commonly apply clinical edits or utilization management. Where specific data elements were not provided, the report notes missing inputs.

This summary serves clinicians, billing professionals, and policy analysts seeking a national perspective on coding and billing for J9264, including how the code is used in outpatient infusion settings and what payers typically cover in broad terms.